Silence Therapeutics PLC
NASDAQ:SLN

Watchlist Manager
Silence Therapeutics PLC Logo
Silence Therapeutics PLC
NASDAQ:SLN
Watchlist
Price: 16.21 USD -7.58% Market Closed
Market Cap: 756.4m USD
Have any thoughts about
Silence Therapeutics PLC?
Write Note

Relative Value

There is not enough data to reliably calculate the relative value of SLN.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SLN Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
275.5
Median 5Y
449.6
Industry
8.1
vs History
vs Industry
Median 3Y
-17.1
Median 5Y
-28.2
Industry
23
vs History
vs Industry
Median 3Y
29.9
Median 5Y
48.8
Industry
23.4
vs History
vs Industry
Median 3Y
30.9
Median 5Y
50.3
Industry
27.3
vs History
vs Industry
Median 3Y
13.9
Median 5Y
22.9
Industry
2.6
vs History
vs Industry
Median 3Y
239.3
Median 5Y
413.4
Industry
8.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
Median 3Y
-12.4
Median 5Y
-21.7
Industry
4.3
vs History
vs Industry
Median 3Y
-12.2
Median 5Y
-21.4
Industry
3.8
vs History
vs Industry
Median 3Y
26
Median 5Y
44.8
Industry
6
vs History
vs Industry
Median 3Y
26.8
Median 5Y
46.3
Industry
3.8
vs History
vs Industry
Median 3Y
6.7
Median 5Y
12
Industry
4.8

Multiples Across Competitors

SLN Competitors Multiples
Silence Therapeutics PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Silence Therapeutics PLC
NASDAQ:SLN
786.2m USD 443.6 -27.5 -21.1 -20.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 380 957.8 -177 666.1 -215 743.3 -213 281.4
US
Abbvie Inc
NYSE:ABBV
302.3B USD 5.4 59.5 14.9 22.9
US
Amgen Inc
NASDAQ:AMGN
160.6B USD 4.9 38 17.7 33.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.3B USD 11.9 -263.2 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
117.6B USD 4.2 933 10.4 10.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 884.6 -480.9 -523.7 -509.7
AU
CSL Ltd
ASX:CSL
138.5B AUD 6.1 34.3 21.1 26.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
90.4B USD 6.5 19.4 17.9 19.9
US
Seagen Inc
F:SGT
39.3B EUR 18.2 -55.7 -59.8 -54
NL
argenx SE
XBRU:ARGX
33.4B EUR 18.2 -127.9 -102.8 -74.9
P/E Multiple
Earnings Growth
UK
Silence Therapeutics PLC
NASDAQ:SLN
Average P/E: 216.8
Negative Multiple: -27.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -177 666.1 N/A
US
Abbvie Inc
NYSE:ABBV
59.5
412%
US
Amgen Inc
NASDAQ:AMGN
38
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
933
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -480.9 N/A
AU
CSL Ltd
ASX:CSL
34.3
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -127.9 N/A
EV/EBITDA Multiple
EBITDA Growth
UK
Silence Therapeutics PLC
NASDAQ:SLN
Average EV/EBITDA: 18.1
Negative Multiple: -21.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 743.3 N/A
US
Abbvie Inc
NYSE:ABBV
14.9
28%
US
Amgen Inc
NASDAQ:AMGN
17.7
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.7 N/A
AU
CSL Ltd
ASX:CSL
21.1
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.8 N/A
EV/EBIT Multiple
EBIT Growth
UK
Silence Therapeutics PLC
NASDAQ:SLN
Average EV/EBIT: 23.5
Negative Multiple: -20.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -213 281.4 N/A
US
Abbvie Inc
NYSE:ABBV
22.9
88%
US
Amgen Inc
NASDAQ:AMGN
33.4
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -509.7 N/A
AU
CSL Ltd
ASX:CSL
26.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -74.9 N/A

See Also

Discover More
Back to Top